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Background. While anabolic hormone deficit is a common finding in heart failure with reduced ejection fraction (HFrEF), few data
are available in heart failure with preserved ejection fraction (HFpEF).Methods. Blood samples were collected for metabolic (total
cholesterol, HDL cholesterol, LDL cholesterol, creatinine, and glucose) and hormonal (IGF-1, DHEA-S, TSH, fT3, fT4, and T)
determination, comparing 30 patients with HFpEF and 20 patients with HFrEF. Total antioxidant capacity was evaluated by using
the spectrophotometric method using the latency time in the appearance of the radical species of a chromogen (LAG, sec) as a
parameter proportional to antioxidant content of the sample. Echocardiographic parameters were also assessed in the two groups.
Results. A high prevalence of testosterone (32% in HFrEF and 72% in HFpEF, p< 0.05) and DHEA-S deficiencies was observed in
HFpEF patients. Echocardiographic parameters did not correlate with hormone values. A significant direct correlation between
T (r2 � 0.25, p< 0.05) and DHEA-S (r2 � 0.19, p< 0.05) with LAG was observed only in HFpEF. Conclusion. Anabolic hormone
deficiency is clearly shown in HFpEF, as already known in HFrEF. Although longitudinal studies are required to confirm the
prognostic value of this observation, our data suggest different mechanisms in modulating antioxidants in the two conditions,
with possible therapeutic implications.
1. Introduction
Chronic heart failure (CHF) is defined as a clinical syndrome
based on an unbalance between cardiac output and metabolic
requirements of organism [1]. Any structural or functional
disorders such as coronary heart disease, hypertension, dia-
betes, cardiomyopathies, heart valve diseases, arrhythmias,
congenital heart defects, anaemia, cocaine abuse, AIDS,
thyroid disorders, radiation, and chemotherapy that reduce
the ability of the ventricle to fill with or eject an adequate
volume of blood may be the cause of this condition. It is a
staggering plague for our times since its prevalence is around
1-2% of the adult population in developed countries, with a
peak ≥10% among people >70 years of age [2–4].
0e main classification of CHF relies on left ventricular
ejection fraction (LVEF), evaluated by echocardiography, or,
less frequently, myocardial scintigraphy and magnetic res-
onance of the heart; its measurement identifies three classes
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of CHF: from the well known and classic heart failure with
reduced ejection fraction (HFrEF), which includes patients
with left ventricular ejection fraction (LVEF) <40%, to heart
failure with preserved ejection fraction (HFpEF), which
comprises patients with LVEF <50%, to the grey area of
LVEF in the range of 40–49%, which describes the new entity
of heart failure with midrange ejection fraction [1]. HFrEF
and HFpEF are the most known subtypes, with a relevant
and increasing literature concerning the last one [5, 6]. 0ey
are different syndromes, with different pathogenesis, path-
ophysiologies, and therapy. In HFrEF, the hinge point is a
direct damage to the heart that leads to reduced left ventricle
contraction [7], whereas in HFpEF, diastolic dysfunction is
the main mechanism involved, with other features con-
tributing to this scenario such as left atrial dysfunction, right
ventricular dysfunction, pulmonary hypertension, and in-
creased vascular stiffness [8–12].
Both the conditions present with a high prevalence of
multihormonal deficiencies [13, 14].0e impairment ofmajor
anabolic systems (somatotropic, adrenal, and gonadal) does
not appear to represent a mere epiphenomenon but is in-
volved in the CHF pathophysiology; especially low serum
testosterone (T), dehydroepiandrosterone-sulfate (DHEA-S),
and insulin-like growth factor (IGF)-1 levels have been
correlated to the symptoms severity and the adverse outcomes
in men suffering from CHF [15–19]. On the contrary, T,
DHEA-S, and IGF-1 are known to regulate oxidative stress in
different manners [20], exerting pro-oxidative effects or
exhibiting an antioxidant power. CHF is a syndrome in which
inflammation and OS play a fundamental role, and, in turn,
this may point to a pivotal role of these hormonal alterations
both in the pathogenesis of CHF and in its treatment.
Total antioxidant capacity (TAC) expresses the whole
effects of nonproteic nonenzymatic antioxidants, as widely
discussed in previous studies [21, 22]. Previously, we have
shown the modulatory action of anabolic hormones on this
parameter and its variations in CHF [20, 23].
0us, the aim of the present study was to explore the
correlation between anabolic hormones, echocardiographic
parameters, and TAC in HFpEF and HFrEF and correlate
them with metabolic parameters (with the aim to better
understand the possible molecular consequences of hor-
monal derangement in these conditions).
2. Materials and Methods
50 subjects involved in this study were admitted to the
University Hospital “Policlinico Gemelli” Dept. of Internal
Medicine and were enrolled after being given an explanation
of purposes and nature of the study, conducted in accor-
dance with the Declaration of Helsinki, as revised in 2013.
0e study protocol was approved by the Institutional review
board of “Medical Pathology” of our University Hospital.
Twenty patients with HFrEF, aged 42–88 years (mean
69.5), and thirty patients with HFpEF, aged 59–90 years
(mean 77.7), were recruited. 0e diagnosis of HFpEF was
established according to the current guidelines of the Eu-
ropean Society of Cardiology [1]. Patients with end-stage
renal disease, liver cirrhosis, and neoplastic or autoimmune
diseases were excluded. All patients were nonsmokers or had
stopped smoking for at least a year. Clinical, anthropo-
metric, and echocardiographic evaluations were achieved,
including the main risk factors for cardiovascular disease.
Prevalence of comorbidities (T2DM, hypertension, atrial
fibrillation, peripheral atherosclerosis, non-end-stage
chronic kidney disease, and COPD) was evaluated. 0e two
groups were not significantly different for age, BMI, and
NYHA classes (all belonged to class II-III).
Between 08.30 and 09.00 a.m., after an overnight fast, a
polyethylene catheter was inserted into the antecubital vein
of one forearm and the blood was collected using a 6mL
vacutainer blood collection tube containing lithium heparin
and immediately centrifuged (4°C at 3000×g for 15min)
with aliquots stored at − 80°C until assayed.
We evaluated metabolic (glycaemia, insulinemia, and
total-HDL-LDL cholesterol) and hormonal pattern (fT3,
fT4, TSH, IGF-1, T, DHEA-S, and NT-proBNP).
Fasting glucose and insulin levels were quantified with
commercial kits using ADVIA automatic analyser (Siemens,
Italy).
Plasmatic concentrations of NT-proBNP, TSH, fT3, fT4,
DHEA-S, T, and IGF-1 were measured by using immu-
nochemiluminometric assays on a Roche Modular E170
analyser (Roche Diagnostics, Indianapolis, IN, USA). 0e
intra- and interassay CV for all hormones were, respectively,
<5.0% and <7.0%.
Normal ranges in our laboratory were NT-proBNP
(>126 pg/ml), TSH (0.4–3.2 μUI/ml), fT3 (2.4–4.2 pg/ml),
fT4 (8.5–16.5 pg/ml), DHEA-S (800–3500 ng/ml), and T
(2.5–8.4 ng/ml). Values equal or below the lower limit of
normal ranges were used to define as deficiency. For IGF-1,
due to the age-related variations, we applied, to define IGF-1
deficiency, criteria of the TOSCA registry referring to the
33th percentile of a population of men with chronic heart
failure (i.e., 122 ng/ml for age range under 55 years, 109 ng/
ml for age range 55–64 years, 102 ng/ml for age range 65–74,
and 99 ng/ml for age range older than 75 years) [13, 17].
A complete echocardiographic evaluation was per-
formed (Echocardiography Philips, Affiniti 70c), measuring
the following parameters: left ventricular ejection fraction
(EF), left ventricular end-diastolic diameter (LVEDD), left
ventricular end-systolic diameter (LV-ESD), left ventricular
end-diastolic volume (LVEDV), left ventricular end-systolic
volume (LV-ESV), septal thickness (IVS), posterior wall
thickness (LV-PW), peak E-wave velocity (E), peak A-wave
velocity (A), E/A ratio, pulsed-wave TDI E′ velocity (E′), E/
E′ ratio, deceleration time (DT), left atrial volume (LAV),
indexed left atrial volume (LAVI), systolic pulmonary artery
pressure (SPAP), tricuspid annular plane systolic excursion
(TAPSE), and tricuspid peak velocity (TPV).
Total antioxidant capacity (TAC) was evaluated with the
method of Rice-Evans and Miller [21], modified as previ-
ously reported [24]. 0e method is based on the interaction
between the system H2O2-metmyoglobin with the chro-
mogen ABTS, whose radical form is spectroscopically de-
tectable. 0e latency time (LAG in sec.) before the
appearance of radical species is proportional to the anti-
oxidant concentration in the sample.
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HOMA-IR was used as an index of insulin resistance and
was obtained from the fasting blood insulin (immunore-
active insulin (IRI)) concentration and the fasting blood
sugar (FBS) level early in the morning, based on the fol-
lowing equation: HOMA-IR� (IRI× FBS)/405.
To estimate the sample sizes, the estimated decrease
prevalence of Tdeficiency between the two groups was set at
20%, based on the only reported work that, at the best of our
knowledge, evaluated these data in HFrEF vs HFpEF pa-
tients [14], with a type I error rate of 0.05 and a type II error
rate of 0.20 (i.e., power of 0.80). Due to the expected effect
size, a total of 44 patients were considered adequate.
0e Mann–Whitney U test was employed to evaluate
differences between the two groups of subjects. A p value of
0.05 was considered statistically significant. Linear regres-
sion analysis was employed to correlate TAC with hormonal
parameters. 0e X square test was used to compare percent
differences between the two groups, when considering the
prevalence of hormone deficiencies and comorbidities.
3. Results
Table 1 shows the echocardiographic parameters: other than
ejection fraction, which was different, by definition, other
differences were found in LVEDV, LVESV, and LAV, all
significantly higher in HFrEF (p< 0.05). On the contrary,
the A wave was significantly higher in HFpEF (p< 0.05).
Comorbidities, as expected, were more prevalent in
HFpEF patients (41% T2DM, 72% hypertension, 36% atrial
fibrillation, 68% peripheral atherosclerosis, 63% non-end-
stage chronic kidney disease, and 36% COPD) than in
HFrEF patients (30% T2DM, 39% hypertension, 44% atrial
fibrillation, 5% peripheral atherosclerosis, 33% non-end-
stage chronic kidney disease, and 16% COPD). X square
analysis showed a significant difference only in hypertension
and peripheral atherosclerotic disease (p< 0.05).
Table 2 shows themetabolic and hormonal parameters in
the two groups. Significant differences were observed in
NT-proBNP, total cholesterol, and T, with higher levels in
HFrEF. LAG values were not significantly different between
the two groups despite higher prevalence of comorbidities in
HFpEF.
Figure 1 shows the graphical representation of percent
prevalence of T deficiency, and DHEA-S levels were under
the normal range in all but two patients. 0e prevalence of T
deficiency was significantly different between the two groups
using the X square test (p< 0.05).
No significant correlation was present when correlating
T or DHEA-S with echocardiographic parameters. On the
contrary, both T and DHEA-S significantly correlated with
LAG values, but only in patients with HFpEF (Figure 2).
4. Discussion
Our data confirm a high prevalence of anabolic hormones
deficit in the two HF subgroups, thus expanding the concept
that anabolic deficiencies are a common finding not only in
HFrEF but also in HFpEF, a poorly explored condition in
this concern. We found a significant difference in the
prevalence of low T in HFpEF; this datum is not fully in
agreement with the only report of hormone evaluation in
HFpEF [13]; however, the difference in age of patients could
contribute to these results. Nevertheless, ageing seems not to
be the only factor influencing hormone picture in these
patients since T levels correlated with LAG in this specific
group, suggesting a possible link between T, oxidative stress,
and cardiac function.
Focusing on T levels, there are several evidences that, in
HFrEF, low levels can represent a bad prognostic sign
[18, 25]. At the state of knowledge, the same conclusion in
HFpEF cannot be sustained due to the lack of large longi-
tudinal studies.
We have neither found correlations between T or
DHEA-S levels and echocardiographic parameters nor
Table 1: Echocardiographic parameters in the two subgroups of
heart failure, with preserved or reduced ejection fraction (HFpEF
and HFrEF, respectively).
HFpEF HFrEF p
LV-EDV (ml) 48.6± 1 146± 13 <0.05
LV-ESV (ml) 31.1± 1.8 91± 10 <0.05
LV-PW (mm) 10.9± 0.6 10.6± 0.6 n.s.
E (mm/s) 575.3± 74.6 347± 152 n.s.
A (mm/s) 789.6± 63.3 334± 110.74 <0.05
EF (%) 55.7± 0.8 36.91± 2 <0.05
E/A 0.8± 0.1 1.10± 0.38 n.s.
E/e′ 11.9± 1.2 12.42± 2.86 n.s.
LAV (ml) 86.4± 8.9 117.86± 12 <0.05
TAPSE (mm) 21.3± 0.9 19.5± 1.21 n.s.
SPAP (mmHg) 35.9± 2.4 42± 4.84 n.s.
LV-EDV� left ventricular end-diastolic volume; LV-ESV� left ventricular
end-systolic volume; LV-PW� left ventricular posterior wall thickness;
E�E wave; A�A wave; e′� e′ wave; EF� ejection fraction; LAV� left atrial
volume; TAPSE� tricuspid annular plane systolic excursion; SPAP� sys-
tolic pulmonary arterial pressure.
Table 2: Mean± SEM values of clinical, metabolic, and hormonal
values in the two subgroups of heart failure, with preserved or
reduced ejection fraction (HFpEF and HFrEF, respectively).
HFpEF HFrEF p
NHYA class II (n� 12) II (n� 10)III (n� 18) III (n� 10)
NT-proBNP (pg/ml) 2862.2± 488.5 7500.16± 2459.5 <0.05
Total cholesterol (mg/
dl) 125.5± 6.9 153.6± 10.9 <0.05
HDL-C (mg/dl) 34.4± 2 44.47± 5.2 n.s.
LDL-C (mg/dl) 75.7± 7.3 91.36± 7.3 n.s.
Creatinine (mg/dl) 1.3± 0.1 1.27± 0.1 n.s.
Insulin (μUI/ml) 11.8± 1.4 25.32± 9.9 n.s.
Glucose (mg/dl) 88.5± 4.7 94.95± 8.4 n.s.
HOMA-IR 2.8± 0.5 3.68± 1.3 n.s.
BMI (kg/m2) 28.7± 1.1 28.03± 1.2 n.s.
IGF-1 (ng/ml) 89.4± 7.1 112.78± 11.8 n.s.
DHEA-S (ng/ml) 438.9± 61.1 564.1± 140.3 n.s.
TSH (μU/ml) 2.5± 0.5 2.82± 1.0 n.s.
fT3 (pg/ml) 2.4± 0.1 2.5± 0.1 n.s.
fT4 (pg/ml) 11.3± 0.5 11.28± 0.5 n.s.
T (ng/ml) 2.4± 0.2 3.55± 0.5 <0.05
LAG (sec) 83± 6.7 75.77± 7.5 n.s.
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dierences comparing patients with low or normal Tand low
or normal DHEA-S.
On the contrary, interesting data emerge when corre-
lating hormonal levels with TAC. Previously, we have shown
that antioxidant systems can counteract OS in patients with
HFrEF when one single hormonal decit is detected, while
such compensation is less eective when more decits ensue
[20].
is is the rst report on TAC in HFpEF. We have found
a signicant correlation between T and DHEA-S with LAG
in such model, while this is not evident in HFrEF.
Two consequences can be argued from these data: rst,
an important role of anabolic hormones in modulating
antioxidant systems in HFpEF; second, dierent patho-
physiological mechanisms underlying the two models of HF.
For both hormones, conicting data are reported in lit-
erature showing pro-oxidant or antioxidant eects,
depending on concentration or dierent models studied. For
instance, DHEA-S administration can induce oxidative stress
in hearts of male wistar rats, dening various histologic
cardiac lesions in rats, such as misshapen cell nuclei, leu-
kocytic inltrates, disorganized myocardial bers, and
echocardiographic alterations (increased LV-PW and LV-
ESD) [26, 27], while it exerts a protective role in the liver of
diabetic rats [28] and rats with obstructive jaundice [29]; in
ovariectomized rats, it improves nitric oxide (NO) produc-
tion, vascular function, and blood pressure levels [30]. e
results of in vivo and in vitro studies have shown that DHEA-S
limits lipid peroxidation [31, 32]. Moreover, oxidative stress
parameters in plasma and in peripheral blood mononuclear
cells in diabetic subjects are signicantly decreased by DHEA-
S treatment [33].
e same double-faced eects are attributed to T. In fact,









Figure 1: Percentage of patients with low testosterone levels in the two forms of heart failure (preserved or reduced ejection fraction, HFpEF
and HFrEF, respectively).


























Figure 2: Graphical representation of correlation between LAG (latency time in the appearance of radical species, see text for the method),
as a parameter of total antioxidant capacity and levels of testosterone T (a) or DHEA-S (b) in patients with heart failure with preserved
ejection fraction (HFpEF).
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stimulated by T, especially in hypertensive animal models
[34]; T also stimulates xanthine oxidase and therefore su-
peroxide generation [35]; finally, acute administration of T
in supraphysiological doses increased NO urinary metab-
olites in healthy subjects [36]. However, it well established a
protective role in ischaemic cardiopathy [37–39]; it is also
known that T has a vasodilatory property via nongenomic
mechanisms [40].
0e literature concerning the T evaluation in CHF has
been extensively reviewed, also for the therapeutic impli-
cation. T deficiency has a key role in some pathophysio-
logical aspects of CHF, such as reduced muscle mass,
abnormal energy handling, dyspnoea, and fatigue [41]. 0e
so-called “muscle hypothesis” is based on functional and
structural alterations of myocytes, which are strongly
influenced by anabolic hormones [42, 43]. Metabolic in-
fluence of T has been also reported [25, 44]. However, some
data are still contrasting: total and free T levels have been
shown to decrease in elderly patients and related to CHF
severity, but they were not independent predictors for
mortality [45]. Long-term epidemiological trials were in
favour of a protective effect of T treatment in the reduction
of major adverse cardiovascular events and mortality [44],
even if other meta-analyses raised doubts on this topic
[46–49].
Our study clearly shows the correlation of the two
hormones with antioxidant systems and is therefore in fa-
vour of a positive role on OS, which is one of the main
players in the pathophysiology of HF.
According to literature, our patients with HFpEF, with a
higher prevalence of obesity and other metabolic comor-
bidities, exhibited a trend toward increased LAG values. It
can be speculated that a further increase in oxidative stress
condition could induce a compensatory increase in anti-
oxidant systems, possibly influencing T levels with a re-
ciprocal vicious circle due to the modulatory role of T itself
on antioxidants. Such correlation is not evident in the
HFrEF group in which a worse cardiac performance or
systemic catabolic status is present in CHF. 0erefore, two
different pathophysiological models seem to be involved in
the two kinds of CHF. As recently proposed, in HFrEF, the
process starts with primary ischaemic or oxidative damage of
cardiomyocytes, whereas in HFpEF, a cascade of events is
increased by the systemic proinflammatory state related to
multiple comorbidities. 0e resultant endothelial damage
leads to microvascular coronary inflammation and, ulti-
mately, to myocardial dysfunction [50].
Nevertheless, there are some potential limitations of the
present study. Firstly, the number of subjects is relatively
small, and our findings need to be validated in a larger
cohort. It is not possible to express a cause-effect relation
between anabolic hormones and antioxidant status. More-
over, only one parameter of antioxidant status has been
evaluated although, in our previous study, the positive effect
of T replacement therapy on TAC in hypogonadal patients
was described [51].
In conclusion, deficit of anabolic hormones is clearly
revealed in HFpEF, as already known in HFrEF. Although
longitudinal studies are needed to confirm a prognostic
value of this observation, our data suggest a different
mechanism in modulating antioxidant systems in these two
conditions. Moreover, a possible therapeutic role of anti-
oxidants needs to be investigated, particularly when T
therapy is contraindicated.
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